RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 2022; 130(11): 723-729
DOI: 10.1055/a-1902-3872
DOI: 10.1055/a-1902-3872
Article
Effect of Aerobic Exercise Training on Circulating Fibroblast Growth Factor-21 Response to Glucose Challenge in Overweight and Obese Men: A Pilot Study
Financial disclosure This work was supported in part by the Grant-in-Aid for Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (20J20892).Clinical Trial Registry This study was a secondary analysis of a study registered with the university hospital medical information network (UMIN) (UMIN000027711), and all participants gave their written informed consent. Registered 9 June 2017, https://center6.umin.ac.jp/cgiopen- bin/ctr_e/ctr_view.cgi?recptno = R000031744.
Abstract
Background and study purpose Fibroblast growth factor-21 (FGF21) is a liver-derived hormone that lowers blood glucose. Although aerobic exercise training also lowers blood glucose, its effect on circulating FGF21levels remains obscure. This study aimed to examine the effect of aerobic exercise training on serum FGF21 levels in overweight and obese men.
Methods A total of 14 overweight/obese men were included in the analyses. Participants attended supervised aerobic exercise training for 12 weeks (three times per week) and completed the standard oral glucose tolerance test pre- and post-exercise training. Plasma glucose, serum insulin, and serum FGF21 levels were measured at fasting and 60 and 120 min after glucose loading.
Results The exercise training reduced plasma glucose and serum FGF21 levels during glucose loading (p<0.05). The change in the area under the curve of plasma glucose was positively correlated with that in the area under the curve of serum FGF21 (r s =0.569, p=0.034).
Conclusion Lowering postprandial circulating FGF21 levels may be associated with the improved glucose tolerance induced by habitual aerobic exercise in overweight and obese men.
Publikationsverlauf
Eingereicht: 03. April 2022
Eingereicht: 03. Juli 2022
Angenommen: 15. Juli 2022
Accepted Manuscript online:
18. Juli 2022
Artikel online veröffentlicht:
21. November 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol 2016; 78: 223-241 DOI: 10.1146/annurev-physiol-021115-105339.
- 2 Cuevas-Ramos D, Almeda-Valdes P, Aguilar-Salinas CA. et al. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr Diabetes Rev 2009; 5: 216-220 DOI: 10.2174/157339909789804396.
- 3 Ogawa Y, Kurosu H, Yamamoto M. et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 2007; 104: 7432-7437 DOI: 10.1073/pnas.0701600104.
- 4 Kaufman A, Abuqayyas L, Denney WS. et al. AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep Med 2020; 1: 100057 DOI: 10.1016/j.xcrm.2020.100057.
- 5 Guo C, Zhao L, Li Y. et al. Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus. J Cell Physiol 2021; 236: 55-67 DOI: 10.1002/jcp.29879.
- 6 Chen C, Cheung BM, Tso AW. et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: A 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34: 2113-2115 DOI: 10.2337/dc11-0294.
- 7 Woo YC, Lee CH, Fong CH. et al. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clin Endocrinol (Oxf) 2017; 86: 37-43 DOI: 10.1111/cen.13229.
- 8 Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V. et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. I J Obes 2015; 39: 121-129 DOI: 10.1038/ijo.2014.76.
- 9 Kruse R, Vienberg SG, Vind BF. et al. Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes. Diabetologia 2017; 60: 2042-2051 DOI: 10.1007/s00125-017-4373-5.
- 10 Korwutthikulrangsri M, Mahachoklertwattana P, Chanprasertyothin S. et al. Serum fibroblast growth factor 21 in overweight and obese Thai children and adolescents: Its relation to glucose metabolism and its change after glucose loading. Clin Endocrinol (Oxf) 2015; 83: 820-827 DOI: 10.1111/cen.12808.
- 11 Lin Z, Gong Q, Wu C. et al. Dynamic change of serum FGF21 levels in response to glucose challenge in human. J Clin Endocrinol Metab 2012; 97: E1224-E1228 DOI: 10.1210/jc.2012-1132.
- 12 Lee SY, Burns SF, Ng KKC. et al. Fibroblast growth factor 21 mediates the associations between exercise, aging, and glucose regulation. Med Sci Sports Exerc 2020; 52: 370-380 DOI: 10.1249/mss.0000000000002150.
- 13 Kim KH, Kim SH, Min YK. et al. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One 2013; 8: e63517 DOI: 10.1371/journal.pone.0063517.
- 14 Slusher AL, Whitehurst M, Zoeller RF. et al. Attenuated fibroblast growth factor 21 response to acute aerobic exercise in obese individuals. Nutr, Metab Cardiovasc Dis 2015; 25: 839-845 DOI: 10.1016/j.numecd.2015.06.002.
- 15 Willis SA, Sargeant JA, Thackray AE. et al. Effect of exercise intensity on circulating hepatokine concentrations in healthy men. Applied Physiol Nutr Metab 2019; 44: 1065-1072 DOI: 10.1139/apnm-2018-0818.
- 16 Taniguchi H, Tanisawa K, Sun X. et al. Endurance exercise reduces hepatic fat content and serum fibroblast growth factor 21 levels in elderly men. J Clin Endocrinol Metab 2016; 101: 191-198 DOI: 10.1210/jc.2015-3308.
- 17 Yang SJ, Hong HC, Choi HY. et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf) 2011; 75: 464-469 DOI: 10.1111/j.1365-2265.2011.04078.x.
- 18 Geng L, Liao B, Jin L. et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep 2019; 26: 2738-2752.e2734 DOI: 10.1016/j.celrep.2019.02.014.
- 19 Hanks LJ, Gutierrez OM, Bamman MM. et al. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Endocrinol 2015; 2: 77-82 DOI: 10.1016/j.jcte.2015.02.001.
- 20 Villarroya J, Gallego-Escuredo JM, Delgado-Angles A. et al. Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. Aging Cell 2018; 17: e12822 DOI: 10.1111/acel.12822.
- 21 Park J, Choi Y, Myoenzono K. et al. Effects of aerobic exercise training on the arterial stiffness and intramyocellular or extramyocellular lipid in overweight and obese men. Clin Exp Hypertens 2020; 42: 302-308 DOI: 10.1080/10641963.2019.1649686.
- 22 Schneider SH, Amorosa LF, Khachadurian AK. et al. Studies on the mechanism of improved glucose control during regular exercise in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1984; 26: 355-360 DOI: 10.1007/BF00266036.
- 23 King DS, Baldus PJ, Sharp RL. et al. Time course for exercise-induced alterations in insulin action and glucose tolerance in middle-aged people. J Appl Physiol 1995; 78: 17-22 DOI: 10.1152/jappl.1995.78.1.17.
- 24 Miyaki A, Maeda S, Yoshizawa M. et al. Effect of habitual aerobic exercise on body weight and arterial function in overweight and obese men. Am J Cardiol 2009; 104: 823-828 DOI: 10.1016/j.amjcard.2009.04.057.
- 25 Kumagai H, Zempo-Miyaki A, Yoshikawa T. et al. Which cytokine is the most related to weight loss-induced decrease in arterial stiffness in overweight and obese men. Endocr J 2018; 65: 53-61 DOI: 10.1507/endocrj.EJ17-0117.
- 26 Zhang X, Yeung DC, Karpisek M. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253 DOI: 10.2337/db07-1476.
- 27 Lakhani I, Gong M, Wong WT. et al. Fibroblast growth factor 21 in cardio-metabolic disorders: A systematic review and meta-analysis. Metabolism 2018; 83: 11-17 DOI: 10.1016/j.metabol.2018.01.017.
- 28 Temelkova-Kurktschiev TS, Koehler C, Henkel E. et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-1834 DOI: 10.2337/diacare.23.12.1830.
- 29 DECODE Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases. Diabetes Care 2003; 26: 688-696 DOI: 10.2337/diacare.26.3.688.
- 30 Xie T, Leung PS. Fibroblast growth factor 21: A regulator of metabolic disease and health span. Am J Physiol Endocrinol Metab 2017; 313: E292-e302 DOI: 10.1152/ajpendo.00101.2017.
- 31 Fisher FM, Chui PC, Antonellis PJ. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789 DOI: 10.2337/db10-0193.
- 32 Hale C, Chen MM, Stanislaus S. et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012; 153: 69-80 DOI: 10.1210/en.2010-1262.